Vistagen therapeutics stock.
On October 14, 2022, Vistagen Therapeutics, Inc. (the “Company”) convened its 2022 Annual Meeting of Stockholders (the “Annual Meeting”).Four of the six proposals described in the Company’s definitive proxy statement for the Annual Meeting (the “Proxy Statement”) were submitted to the Company’s stockholders for a vote at the Annual Meeting, after which time the Annual Meeting ...
VTGN has an Altman Z-Score of -5.47 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for VistaGen Therapeutics, Inc. (VTGN) stock, including valuation metrics, financial numbers, share information and more.Aug. 10, 2023 5:22 PM ET Vistagen Therapeutics, Inc. (VTGN) By: Deepa Sarvaiya, SA News Editor 2 Comments VistaGen Therapeutics press release ( NASDAQ: VTGN ): Q1 GAAP EPS of -$0.94 misses by $0.08 .On Tuesday 10/24/2023 the closing price of the VistaGen Therapeutics Inc Registered Shs share was $3.07 on NAS. Compared to the opening price on Tuesday 10/24/2023 on NAS of $2.99, this is a gain ...Dec 6, 2022 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are ... The U.S. Phase 1 data build on successful Phase 1 and Phase 2A clinical studies of itruvone previously conducted outside the U.S. Itruvone was well-tolerated and demonstrated a favorable safety and...
VistaGen Therapeutics has raised a total of. $154.8M. in funding over 8 rounds. Their latest funding was raised on Oct 2, 2023 from a Post-IPO Equity round. VistaGen Therapeutics is registered under the ticker NASDAQ:VTGN . VistaGen Therapeutics is funded by 9 investors. BVF Partners and TCG Crossover are the most recent investors.Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced positive top-line results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of …Dec 21, 2022 · Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to ...
Press Releases. Year. All Years. Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results. Nov 09, 2023. Vistagen to Present at Stifel 2023 Healthcare Conference. Nov 08, 2023. Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific …
Vistagen Therapeutics Inc ( VTGN) is up 0.89% today. VTGN has an Overall Score of 58. Find out what this means to you and get the rest of the rankings on VTGN! VTGN stock closed at $3.37 and is up $0.03 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade …VTGN Earnings Date and Information. Vistagen Therapeutics last issued its quarterly earnings results on November 9th, 2023. The reported ($0.66) earnings per share for the quarter. The company earned $0.28 million during the quarter. Vistagen Therapeutics has generated $0.00 earnings per share over the last year.With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.3.5900. +0.2400. +7.16%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript August 13, 2023 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 ...
Founded Date 1998. Founders H. Ralph Snodgrass. Operating Status Active. Last Funding Type Post-IPO Equity. Stock Symbol NASDAQ:VTGN. Company Type For Profit. Contact Email [email protected]. Phone Number 6505589566. VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to …
Nov 30, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00.
This is where VistaGen Therapeutics comes into play. Shares of the penny stock were trading at $1.68 as of the closing bell on Friday. That all changed during Monday’s premarket session when VTGN stock exploded to highs of $60. VTGN Stock Catalyst. That 3,471% move was triggered by news of positive Phase 3 data.Of the 54 institutional investors that purchased Vistagen Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Commodore Capital LP ($8.09M), Renaissance Technologies LLC ($4.11M), MAI Capital Management ($2.66M), State Street Corp ($2.29M), Goldman …Find the latest Institutional Holdings data for VistaGen Therapeutics, Inc. Common Stock ... Institutional Holdings information can be used to gauge the volatility and value on the company’s stock.Track VistaGen Therapeutics Inc (VTGN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsSocial Anxiety Disorder | Vistagen Therapeutics, Inc. Based on the 2021 National Health and Wellness Survey, social anxiety disorder (SAD) affects over 25 million Americans, with onset typically in the mid-teens or earlier, and is diagnosed slightly more frequently in females than males. SAD can be viewed as a series of acute, socially ...
VistaGen drops 80% as late-stage study for anxiety therapy fails. Clinical-stage biotech VistaGen Therapeutics ( NASDAQ: VTGN) announced on Friday that the company’s PALISADE-1 Phase 3 clinical ...Learn more about whether Vistagen Therapeutics Inc is a good stock to buy or sell based on recent news as well as its key financial metrics. Read on to find out how grades on certain investment factors and determine whether it meets your investment needs. Latest Vistagen Therapeutics Inc Stock NewsVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript. Get the latest Vistagen Therapeutics, Inc. (VTGN) stock news and headlines to help you in your trading and investing ...The VistaGen Therapeutics Inc stock price gained 7.16% on the last trading day (Friday, 24th Nov 2023), rising from $3.35 to $3.59. During the last trading day the stock fluctuated 8.30% from a day low at $3.37 to a day high of $3.65. The price has risen in 8 of the last 10 days and is up by 24.22% over the past 2 weeks.Founded Date 1998. Founders H. Ralph Snodgrass. Operating Status Active. Last Funding Type Post-IPO Equity. Stock Symbol NASDAQ:VTGN. Company Type For Profit. Contact Email [email protected]. Phone Number 6505589566. VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to …
View VistaGen Therapeutics, Inc VTGN investment & stock information. Get the latest VistaGen Therapeutics, Inc VTGN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Get the latest Vistagen Therapeutics Inc (VTGN) stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's financial performance, balance sheet, cash flow, and market outlook for the first quarter of 2024.
Shares of VistaGen Therapeutics ( VTGN -6.17%) were soaring 22.1% as of 11:27 a.m. EST on Thursday. The big jump came after Jefferies analyst Andrew Tsai initiated coverage on the stock with a buy ...Find the latest SEC Filings data for VistaGen Therapeutics, Inc. Common Stock (VTGN) at Nasdaq.com.VistaGen Therapeutics Inc stock price live 3.650, this page displays NASDAQ VTGN stock exchange data. View the VTGN premarket stock price ahead of the market session or assess the after hours quote.Jun 30, 2021 · Shares of VistaGen Therapeutics ( VTGN 0.15%) were jumping 15.5% higher as of 3:21 p.m. EDT on Wednesday. The big gain came after the company announced results for its fiscal year 2021 and ... The U.S. Phase 1 data build on successful Phase 1 and Phase 2A clinical studies of itruvone previously conducted outside the U.S. Itruvone was well-tolerated and demonstrated a favorable safety and...Aug 7, 2023 · Vistagen Therapeutics (NASDAQ: VTGN) stock is surging to impressive levels today on news of some positive trial results. The pharmaceutical producer has been struggling all year, dipping into ...
Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst markets.businessinsider.com - November 14 at 6:25 PM: VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript finance.yahoo.com - November 11 at 5:51 PM
William Blair initiated coverage on VistaGen Therapeutics Inc VTGN, a clinical-stage biopharmaceutical company focused on developing next-generation …
Nov 9, 2023 · MT. Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating. Oct. 17. MT. Maxim Downgrades VistaGen Therapeutics to Hold From Buy. 2022. MT. Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8. Oct 2, 2023 · At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen ... The recent price decline of 15% in VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) stock may have disappointed insiders who bought US$190k worth of shares at an average price of US$0.17 in the past 12 ...The latest price target for Vistagen Therapeutics ( NASDAQ: VTGN) was reported by Stifel on Tuesday, November 14, 2023. The analyst firm set a price target for 12.00 expecting VTGN to rise to ...Vistagen Therapeutics (NASDAQ: VTGN) stock is surging to impressive levels today on news of some positive trial results.The pharmaceutical producer has been struggling all year, dipping into penny ...The two main types of listening are discriminative and comprehensive. On top of the two basic types of listening, there are more specific types: informational, critical, therapeutic and appreciative.VistaGen Therapeutics Inc (NASDAQ:VTGN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) …(NASDAQ: VTGN) Vistagen Therapeutics currently has 27,023,038 outstanding shares. With Vistagen Therapeutics stock trading at $2.57 per share, the total value ...Dec 1, 2023 · Valuation metrics show that VistaGen Therapeutics, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ... See the latest Vistagen Therapeutics Inc stock price (VTGN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.
2 brokers have issued 1-year target prices for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 475.3% from the stock's current price.Dec 1, 2023 · Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly Results; Section 16 Filings; Corporate Governance Executive Team; Board Committees; Documents & Charters Vistagen Therapeutics ( NASDAQ: VTGN) added ~17% on Tuesday after Stifel initiated its coverage with a Buy recommendation citing a potential blockbuster opportunity for its anxiety disorder drug ...Instagram:https://instagram. vpu holdingse mini sandp 500 futures brokersbest online stock trading courseslegalshield insurance SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 8, 2022-- Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) … is skywatch.ai legitafirm stock The recent price decline of 15% in VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) stock may have disappointed insiders who bought US$190k worth of shares at an average price of US$0.17 in the past 12 ... stock c3 ai VistaGen Therapeutics Inc (NASDAQ:VTGN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more ...Press Releases. Year. All Years. Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results. Nov 09, 2023. Vistagen to Present at Stifel 2023 Healthcare Conference. Nov 08, 2023. Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific …